Health17:50 · Aug 13

European Drug Shortages Raise Concerns Over Potential Impact on Israel's Supply

Now 14Right

Translated & summarized from Now 14 by baba

Key points

01EMA holds meetings to tackle critical drug shortages in Europe, including cancer drugs ifosfamide and cyclophosphamide.
02Over 200 active pharmaceutical ingredients are deemed critical by EMA due to their essential healthcare roles.
03Supply issues arise from manufacturing problems, raw material shortages, and global resource competition.
04EMA collaborates with international regulators and suppliers to manage shortages and issued recommendations in July 2023.
05Israel, dependent on global supply chains, monitors potential impacts but no new shortages are reported locally yet.
06The EU has enhanced mechanisms for shortage prevention and cross-country support during crises.

In this story

People

Yael Anker

OrganizationsEuropean Medicines Agency, EMA, FDA, SPOC, MSSG

PlacesEurope, Israel, European Union

The story · English

The European Medicines Agency (EMA) recently held a meeting to address ongoing drug shortages and supply disruptions affecting Europe. The agency monitors critical medications and coordinates with EU member states to mitigate patient harm. Among the most affected drugs are ifosfamide and cyclophosphamide, essential chemotherapy agents, which have faced persistent supply unpredictability and shortages since mid-2023. EMA has engaged with manufacturers, alternative suppliers, and international regulators like the FDA to manage these shortages and issued recommendations in July to improve availability and reduce patient impact.

Currently, over 200 active pharmaceutical ingredients are classified by EMA as critical due to their essential role in healthcare and limited treatment alternatives. The shortages stem from various causes including manufacturing issues, raw material scarcity, and global competition for resources. The COVID-19 pandemic and geopolitical tensions have further exposed vulnerabilities in drug supply chains.

While EMA's recent discussions do not indicate new shortages in Israel or specify which drugs might be affected locally, the interconnected nature of global supply chains means European shortages could influence Israeli drug availability. The impact depends on Israel's existing stock, sources of procurement, and availability of alternative treatments. Israel, reliant on international supply chains, is closely monitoring the situation.

The EU has strengthened mechanisms to prevent and manage drug shortages, including the SPOC group for information exchange and the MSSG for coordinating urgent responses. A solidarity mechanism also allows EU countries to request assistance during critical shortages. For Israel, these developments serve as a warning to maintain vigilance rather than evidence of immediate supply problems. Further clarity will emerge once EMA publishes detailed outcomes from its latest meeting and assesses local supply conditions.

Read the original at Now 14